Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

@article{Furman2014IdelalisibAR,
  title={Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.},
  author={Richard R. Furman and Jeff P. Sharman and Steven E. Coutr{\'e} and Bruce D Cheson and John M Pagel and Peter Hillmen and Jacqueline C Barrientos and Andrew D. Zelenetz and Thomas J. Kipps and Ian W Flinn and Paolo Ghia and Herbert A Eradat and Thomas J. Ervin and Nicole Lamanna and Bertrand Coiffier and Andrew R. Pettitt and Shuo Nan Ma and Stephan Stilgenbauer and Paula Cramer and Maria Aiello and Dave M. Johnson and Langdon L. Miller and Daniel Li and Thomas M. Jahn and Roger Delemere Dansey and Michael J Hallek and Susan O'brien},
  journal={The New England journal of medicine},
  year={2014},
  volume={370 11},
  pages={997-1007}
}
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. METHODS In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

4 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy .
Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy .
All Topics